Skip to main content

PRTA

Stock
Health Care
Biotechnology

Performance overview

PRTA Price
Price Chart

Forward-looking statistics

Beta
1.91
Risk
77.64%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Company info

SectorHealth Care
IndustryBiotechnology
Employees160
Market cap$1.1B

Fundamentals

Enterprise value-$81.0M
Revenue$137.9M
Revenue per employee—
Profit margin-79.94%
Debt to equity2.33

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$2.05
Dividend per share$0.20
Revenue per share$2.56
Avg trading volume (30 day)$14M
Avg trading volume (10 day)$11M
Put-call ratio—

Macro factor sensitivity

Growth-1.1
Credit+10.3
Liquidity+1.4
Inflation-5.8
Commodities-1.9
Interest Rates-1.1

Valuation

Dividend yield3.19%
PEG Ratio-1.50
Price to sales2.51
P/E Ratio-1.50
Enterprise Value to Revenue-0.59
Price to book0.79

Upcoming events

Next earnings dayAugust 6, 2025
Next dividend day—
Ex. dividend dayMarch 28, 2023

News

PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects?

Prothena slashes 63% of its workforce and axes birtamimab after trial failure, reshaping its pipeline and financial outlook. Shares plunge 53.5% YTD.

Zacks Investment Research (July 4, 2025)
Why Is Prothena Stock Trading Lower On Tuesday?

Prothena Corporation plc PRTA released data from the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with AL amyloidosis on Friday.

Benzinga (May 27, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free